In developing an orphan drug policy, Canada must ensure that all orphan drugs for rare diseases — both old and future drugs — should be priced fairly so that Canadians may access life-saving therapy, argue authors of a new Canadian analysis.
In developing an orphan drug policy, Canada must ensure that all orphan drugs for rare diseases — both old and future drugs — should be priced fairly so that Canadians may access life-saving therapy, argue authors of a new Canadian analysis.